Status:
COMPLETED
Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.
Eligibility Criteria
Inclusion
- Diagnosis of melanoma
Exclusion
- Age less than 18 years old
Key Trial Info
Start Date :
June 23 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 28 2017
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT03438279
Start Date
June 23 2015
End Date
December 28 2017
Last Update
February 19 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Boston, Massachusetts, United States, 02199